Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer: Castrate Resistant
Join Andrew J. Armstrong, MD, ScM and Bridget Koontz, MD from Duke Cancer Institute as they present their expertise on a range of cases pertaining to castrate resistant prostate cancer (CRPC).
Prostate cancer has become the most commonly diagnosed non-skin cancer in men. Although androgen deprivation therapy is an effective first-line treatment for advanced disease, almost all cases eventually become resistant. Treatment of CRPC has entered a new era with the dramatic expansion in effective agents. With the wide range of treatment choices, careful patient selection is paramount to maximize benefit and avoid unnecessary side effects. Treatment decisions must be tailored individually depending on the presence or absence of symptoms, life expectancy, and overall health of the patient. With the plethora of new agents developed in recent years for CRPC, clinicians need to understand not only the selection criteria for each agent, but also optimal sequencing strategies to help patients navigate through the many options for initial and subsequent treatment.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Outline novel therapies for CRPC that received approval in recent years
- Assess available treatment options appropriate to different settings based on symptoms, overall health, and risk-benefit ratios
Andrew J. Armstrong, MD, ScM
Duke Cancer Institute
Bridget Koontz, MD
Duke Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-023-L01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation